AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04484337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.
Study NCT04484337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir sodium (Oral Lead In)
Description: CAB will be available as 30 mg tablets for oral administration.
Study NCT04484337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 400 mg/mL
Description: CAB 400 mg/mL will be available for administration by IM injection or SC Injection.
Study NCT04484337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir 200 mg/mL
Description: CAB 200 mg/mL will be available for administration by IM injection or SC Injection.
Study NCT04484337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical non-steroidal anti-inflammatory drug
Description: Non-steroidal anti-inflammatory drug will be available for topical application
Study NCT04484337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical steroid
Description: Steroid will be available for topical application
Study NCT04484337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo creams/gels
Description: Placebo creams/gels will be available for topical application
Study NCT04484337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Description: rHuPH20 will be available for administration by SC Injection
Study NCT04484337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Description: rHuPH20 will be available for administration by SC Injection
Study NCT01107236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-6118
Description: Single dose
Study NCT01107236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
Study NCT01107236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Single dose
Study NCT02149303 — intervention group
Intervention type: DRUG
Intervention: Dabigatran 75 mg
Description: PO BID
Study NCT02149303 — intervention group
Intervention type: DRUG
Intervention: Dabigatran 150 mg
Description: PO BID
Study NCT00090038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Dose, schedule,and duration specified in protocol
Study NCT02207309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Study NCT02207309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Pazopanib)
Study NCT04324008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constic
Description: Flowable resin composite
Study NCT04324008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-ænial Universal Flo
Description: Flowable resin composite
Study NCT04324008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetric N-Flow (self-etch)
Description: Tetric N-Flow (Tetric N-Bond Universal, self-etch mode)
Study NCT04324008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetric N-Flow (etch&rinse)
Description: Tetric N-Flow (Tetric N-Bond Universal, etch\&rinse mode)
Study NCT01462110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 19416-154-1
Description: 0.15% ethyl lauroyl arginate HCl-containing mouthrinse
Study NCT01462110 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: W002194-0221P
Description: 5% hydroalcohol mouthrinse
Study NCT02454751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: One time dose of 50mcg of fentanyl administered intranasally
Study NCT04200547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunomonitoring-based follow-up
Description: Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. 3 months after the surgery, serum levels of adalimumab will be measured:~* If the level is below 5ug/mL, adalimumab treatment will be increased to every other week until the end of the study.~* If adalimumab level in the serum is above 5ug/mL, the treatment's frequency will be maintained until the end of the study.
Study NCT04200547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. If clinical relapse (CDAI > 220 together with an increase of 70 points) and biological relapse (CRP > 10mg/mL and fecal calprotectin > 100 ug/g) occur, frequency of adalimumab treatment will be increased to once a week.
Study NCT01712139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan and Hydrochlorothiazide
Study NCT01712139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avalide
Study NCT03112486 — intervention group
Intervention type: PROCEDURE
Intervention: blood draw
Description: Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72, 96, 120, 144 (10 draws total). Each draw would be approximately 20 mL of blood (but no less than 10 mL).
Study NCT00656175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: raltegravir
Study NCT02360787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy restriction
Study NCT02360787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Almonds (15% kcal/day)
Study NCT02980406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP
Description: Fermentable oligo-, di- and monosaccharides and polyols are poorly absorbed carbohydrates that are known to cause symptoms in IBS patients.
Study NCT02980406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose (control)
Description: Glucose is not a FODMAP.
Study NCT01537848 — intervention group
Intervention type: PROCEDURE
Intervention: EUS guided transmural drainage
Description: Puncture of the collection is done under EUS guidance using a linear echoendoscope (FG-3830UT, Pentax or Olympus GF-UCT140/180 or forward viewing scope (Olympus)) with a 19G echoTip needle or a cystotome (Cook Medical Inc.). Then a 0.035 guidewire is inserted in the collection and the hole is enlarged with a cystotome (Cook Medical) or a 6.5F diathermic sleeve (Endoflex) and sometimes if needed a 6-8mm CRE balloon (Boston Scientific) before stenting with one or two double pigtail plastic stents (Cook Endoscopy, Endoflex). A nasocystic drain was also put whenever needed. If only a single stent could be placed in the first attempt, a subsequent procedure is scheduled for insertion of additional stents after dilation of the tract. There isn't any specific drug given during the procedure.
Study NCT02130388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Zinc
Study NCT03135509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 gelatin capsules
Study NCT02118779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural change intervention
Description: The intervention is cognitive behaviour therapy (CBT). The CBT consists of six different modules. All patients will start with individual goal setting and psycho-education about the role of cognitive-behavioural variables in the disabilities patients' experience. The patient formulates his or her treatment goals in concrete terms and later on in the therapy the goals are realised step by step by the patient. The treatment is tailored to the patient's problems: which of the six modules a patient will receive is dependent on the scores on measures that have been collected at baseline assessment. Based on our previous experience with modular interventions we expect that most patients will receive less than four modules.
Study NCT04536805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
Study NCT04536805 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy)
Description: Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy day 0 to day 10
Study NCT04536805 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT) 36 Gy
Description: Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy day 0 to day 12
Study NCT04536805 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT) 25 Gy
Description: Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5x 5 Gy day 0 to day 10
Study NCT03812445 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus,Bifidobacterium lactobacillus,Lactobacillus paracasei,Lactobacillus rhamnosus and Lactobacillus fermentium with does of 8\*10\^9 Colony-Forming Units(CFU) \*2/d for 3 months.
Study NCT00992017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H1N1) monovalent vaccine
Description: Two 15-microgram intramuscular vaccine injections given together form one dose; two doses (four total injections) are given 21 days apart
Study NCT02928523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Fecal Microbiota Transplantation
Study NCT03207997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: unenhanced MR sequences
Description: 2 additional unenhanced MR sequences
Study NCT03207997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unenhanced MR sequences
Description: 2 additional unenhanced MR sequences
Study NCT04057378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy
Description: Electrically induced convulsion under anesthesia
Study NCT03472612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal
Description: Short-term withdrawal of CPAP therapy in moderate to severe OSA
Study NCT00697853 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study NCT00697853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 2-dose intramuscular injection
Study NCT02487797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT02487797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT02487797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Study NCT02487797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9%
Study NCT04298827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unimodal
Description: Patients will receive physical therapy alone.
Study NCT04298827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trimodal
Description: Patients will receive physical therapy, nutrition counseling, and cognitive behavioral therapy in the form of group counseling.
Study NCT04540328 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-surgical periodontal treatment
Study NCT04213092 — intervention group
Intervention type: PROCEDURE
Intervention: ERCP+LC
Description: Patients in this group underwent a single setting ERCP and Laparoscopic cholecystectomy.
Study NCT04213092 — intervention group
Intervention type: PROCEDURE
Intervention: OC+CBD
Description: Patients in this group underwent a single setting open cholecystectomy and open CBD exploration.
Study NCT03973541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy with Exposure therapy
Description: Treatment will be conducted for 10 consecutive weekly 60 min sessions. In the first two treatment conditions sessions are scheduled as follows: Session one: Building a therapeutic alliance and psycho-education about social anxiety and safety and avoidance behaviors. Session two to four: Cognitive restructuring. Session five to nine: Exposure in either in vivo or VR. Session 10: Relapse prevention. Sessions one to four and ten are identical in the two of three treatment arms.
Study NCT03973541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with Exposure therapy
Description: Treatment will be conducted for 10 consecutive weekly 60 min sessions. In the first two treatment conditions sessions are scheduled as follows: Session one: Building a therapeutic alliance and psycho-education about social anxiety and safety and avoidance behaviors. Session two to four: Cognitive restructuring. Session five to nine: Exposure in either in vivo or VR. Session 10: Relapse prevention. Sessions one to four and ten are identical in the two of three treatment arms.
Study NCT03973541 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Relaxation Therapy
Description: Relaxation Therapy
Study NCT01689441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Study NCT01689441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02477358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left Tooth Platelet Rich Fibrin; Right Tooth Implant Alone
Description: All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy will be applied to the left tooth socket only. The right tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
Study NCT02477358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right Tooth Platelet Rich Fibrin; Left Tooth Implant Alone
Description: All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy to the right tooth socket only. The left tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
Study NCT02849080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once-daily.
Study NCT02849080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Oral administration once-daily.
Study NCT04328428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Use one acupuncture needle insert in a acupoint.
Study NCT04328428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Use one acupuncture needle insert in a acupoint.
Study NCT01388933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU-100
Description: 15g daily, orally as 5g three times daily for 8 consecutive weeks
Study NCT01388933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: 15g as 5g three times daily, orally for 8 consecutive weeks
Study NCT03223155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients in Sequential Arm will begin treatment with nivolumab (given with ipilimumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with nivolumab (given with ipilimumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with nivolumab 3 mg/kg as a 30-minute infusion +/- 10 minutes every 2 weeks for a maximum of 24 months. Patients will receive treatment on days 1, 15, and 29 of each 6 week cycle.
Study NCT03223155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients in Sequential Arm will begin treatment with ipilimumab (given with nivolumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with ipilimumab (given with nivolumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with ipilimumab 1 mg/kg as a 30-minute +/- 10 minutes infusion every 6 weeks for a maximum of 24 months. Patients will receive treatment on day 1 of each 6 week cycle.
Study NCT03223155 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: All patients will receive 3 or 5 fractions of radiation as determined by the location of the lesions to be irradiated. There should be a minimum of 40 hours between treatments for an individual lesion. However, a patient may receive radiation for different lesions on consecutive days. Starting dose depends on metastasis locations.
Study NCT02895295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert Recommendation
Description: Decision support tool that provides personalized information on the financial implications of enrolling in different plans and expert recommendations of particular plans.
Study NCT02895295 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Analysis
Description: Decision support tool that provides personalized information on the financial implications of enrolling in different plans.
Study NCT02895295 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and provided with a list of resources available in the community to help them choose a prescription drug plan.
Study NCT02385565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat diet
Description: high fat diet as 10 % proteins, 30 % lipids, 60 % carbohydrates
Study NCT02385565 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal fat diet
Description: high fat diet as 10 % proteins, 45 % lipids,45 % carbohydrates
Study NCT02213588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AOX blend
Description: Antioxidant supplement
Study NCT02213588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04303416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin solution
Description: plasma exchange with albumin, one per week for one month, then one per month for 5 months
Study NCT00622492 — intervention group
Intervention type: OTHER
Intervention: echocardiography Doppler sonography, blood and urine sampling
Description: data registration and collection at standard intervals from directly before cannulation until 24 hours after decannulation from ECMO
Study NCT00814723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluvastatin
Description: 80 mg MR, 12 weeks
Study NCT00814723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvastatin plus ezetimibe
Description: fluvastatin 80 mg MR plus ezetimibe 10 mg
Study NCT04437836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evaluation of high dose rifampicin in children
Description: Evaluation of severity of adverse event from grade 1 to 5
Study NCT01472133 — intervention group
Intervention type: OTHER
Intervention: Recording of 12 lead ECG
Description: Recording of 12 lead ECG
Study NCT01472133 — intervention group
Intervention type: OTHER
Intervention: Recording of lying and standing blood pressure
Description: Recording of lying and standing blood pressure
Study NCT01472133 — intervention group
Intervention type: OTHER
Intervention: Recording of chest wall movement
Description: Recording of chest wall movement
Study NCT01472133 — intervention group
Intervention type: OTHER
Intervention: Recording of heart rate variability
Description: Done during deep breathing and a valsalva manoeuvre
Study NCT01472133 — intervention group
Intervention type: OTHER
Intervention: Recording of ECG and Pulse oximeter waveform at rest
Description: For 10 mins
Study NCT01472133 — intervention group
Intervention type: OTHER
Intervention: Recording of ECG and Pulse oximeter waveform during exercise
Description: Recording of ECG and Pulse oximeter waveform during exercise
Study NCT01440634 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supervised exercise Program
Description: Supervised exercise Program consist of six months of supervised, intermittent track walking. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month. During each exercise session, individuals will be encouraged to walk at a speed of approximately 2 mph until they achieve leg pain or discomfort on walking of moderate severity.Individuals are then allowed to have a brief period of standing or sitting rest to permit symptoms to resolve before they resume exercise.
Study NCT02029274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
Study NCT02029274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to BAF312 as tablets for oral administration.
Study NCT04235166 — intervention group
Intervention type: OTHER
Intervention: Current risk scores
Description: Current risk scores for assessing the prognosis of acute upper gastrointestinal bleeding in cirrhosis were used.